Poor
Not Aligned
Patient Risk:
Moderate
Summary
Many claims are not supported by the provided naproxen label excerpts (especially specific statin–naproxen interaction framing). Some general NSAID risk-reduction and GI/bleeding interaction concepts align with the label, but multiple unsupported/overgeneralized statements substantially reduce alignment.
Category Scores
Accurate Statements
If taking both naproxen and a statin, using the lowest effective naproxen dose for the shortest time is recommended.
Label 2.1 general dosing instructions:
Avoid administration of more than one NSAID at a time.
Label 5.2 strategies to minimize GI risks include: avoid administration of more than one NSAID at a time.
NSAIDs like naproxen can irritate the stomach lining and increase bleeding risk.
Label 5.2: NSAIDs cause serious GI adverse events including inflammation and bleeding.
The risk of kidney strain from NSAIDs increases if the person already has kidney disease, is dehydrated, is older, or takes other medicines that affect kidneys such as certain blood pressure medicines and diuretics.
Not assessable from the provided label excerpts (no renal warnings text included in the supplied sections).
Unsupported Statements
For most people, naproxen can be taken with statins.
No label support provided regarding statin coadministration.
The combination of naproxen with a statin raises certain risks that depend on the statin, dose, age, kidney function, and other medicines being taken.
No label support provided for statin-specific interaction risk dependencies.
Statins and naproxen are not known for a direct, classic 'can’t mix' interaction in most patients.
No label support provided for any statin–naproxen interaction characterization.
The bigger concern when combining naproxen with a statin is safety rather than a guaranteed drug–drug reaction.
No label support provided for statin–naproxen combination framing.
Practical risk of combining naproxen with a statin can vary because some people are more prone to side effects based on kidney/liver status.
No label support provided for statin–naproxen-specific risk variability.
Practical risk of combining naproxen with a statin can vary because drug levels can be affected by other medications taken alongside both drugs.
No label support provided for statin-related pharmacokinetic interactions.
There is not a well-known, specific interaction where one statin classically becomes unsafe with naproxen for everyone.
No label support provided for statin-class-specific interaction safety statements.
The combination of a statin with naproxen is a reason to avoid unnecessary long-term NSAID use.
The label supports lowest effective dose/shortest duration for NSAID use generally, but the specific claim tying this to statin combination is unsupported.
The combination of a statin with naproxen is a reason to seek care if symptoms occur.
No label support provided linking seeking care specifically to statin coadministration.
Statins can affect liver enzymes in some people.
No label support provided for statins.
Naproxen can also affect the liver in rare cases.
No liver adverse event statements provided in the supplied label excerpts.
Naproxen is associated with GI bleeding signs such as black/tarry stools, vomiting blood, and severe stomach pain.
Label excerpt provided describes GI bleeding as serious and can occur, but specific symptom examples were not provided in the supplied text.
Kidney/dehydration concerns associated with naproxen can include much less urine, sudden swelling, severe dizziness, and inability to keep fluids down.
No renal warning text or symptom examples provided in the supplied label excerpts.
Muscle problems (especially with unusual weakness or dark urine) can occur with statins.
No label support provided for statins.
Liver-related symptoms associated with statins can include yellowing of the skin or eyes, severe fatigue, and dark urine.
No label support provided for statins.
Avoiding naproxen if there is known kidney disease unless the clinician approves a specific plan is recommended.
No kidney disease contraindication/avoidance statement provided in the supplied label excerpts.
Be cautious with alcohol when using naproxen.
No alcohol caution statement provided in the supplied label excerpts.
Avoid adding aspirin unless told to.
Label excerpt does discuss aspirin-related increased GI adverse reactions, but the directive 'avoid adding aspirin unless told to' is not directly supported as written.
If naproxen is risky for a person (for example, due to kidney disease, ulcers, or bleeding risk), clinicians may consider alternatives such as acetaminophen or other non-NSAID options depending on the cause of pain and medical history.
No alternative analgesic guidance (acetaminophen/non-NSAID) provided in the supplied label excerpts.
Contradictions
Low
AI Statement
Statins and naproxen are not known for a direct, classic 'can’t mix' interaction in most patients.
Label Reference
Label 7 Drug Interactions indicates clinically significant interactions with certain drug classes (e.g., anticoagulants/antiplatelets/SSRIs/SNRIs/aspirin), but no statin-specific claims are provided in the supplied excerpt; therefore this statement is best categorized as unsupported rather than a direct contradiction based on provided text.
Important Omissions
No citation of the label’s CABG surgery contraindication or hypersensitivity/NSAID allergy contraindications, which are explicit contraindications in the provided labeling.
Importance:
Moderate
For drug-interaction safety, the label excerpt specifically names monitoring risks with concomitant use of naproxen and anticoagulants/antiplatelet agents (e.g., warfarin, aspirin) and SSRIs/SNRIs; the response does not reflect these specific on-label interaction categories (it focuses on statins instead).
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several statements about statin–naproxen coadministration and specific symptom/organ concerns are unsupported by the supplied label excerpts. While general NSAID dose-duration and GI risk concepts align, the response under-represents explicit on-label contraindications and named interaction/monitoring categories (anticoagulants/antiplatelets/SSRIs/SNRIs), which could lead to incomplete label-consistent risk communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
The response makes numerous statin–naproxen interaction assertions and symptom examples not supported by the provided FDA label excerpts, and omits explicit label contraindications and named interaction/monitoring categories.
Suggested Improvement
Limit claims to label-supported statements: (1) lowest effective dose/shortest duration; (2) GI bleeding/ulceration/perforation and risk-minimization strategies; (3) explicitly listed contraindications (CABG setting and NSAID/Aspirin hypersensitivity reactions) and (4) label-supported drug interaction classes and monitoring guidance (anticoagulants/antiplatelets/SSRIs/SNRIs, aspirin). Avoid statin-specific ‘can be taken’/‘no classic can't mix’ statements unless the provided label text explicitly addresses statins.